

Published in final edited form as:

Mol Nutr Food Res. 2011 September ; 55(9): 1411–1422. doi:10.1002/mnfr.201100225.

Acrolein-Induced Dyslipidemia and Acute Phase Response Independently of HMG-CoA Reductase

Daniel J. Conklin¹, Russell A. Prough², Peter Juvan³, Tadeja Rezen³, Damjana Rozman³, Petra Habertzettl¹, Sanjay Srivastava¹, and Aruni Bhatnagar^{1,2}

¹Diabetes and Obesity Center, University of Louisville, Louisville, KY 40202

²Department of Biochemistry and Molecular Biology, University of Louisville, Louisville, KY 40202

³Centre for Functional Genomics and Bio-Chips (CFGBC), Institute of Biochemistry, Faculty of Medicine, University of Ljubljana, Zaloska 4, SI-1000 Ljubljana, Slovenia

Abstract

Scope—Aldehydes are ubiquitous natural constituents of foods, water and beverages. Dietary intake represents the greatest source of exposure to acrolein and related aldehydes. Oral acrolein induces dyslipidemia acutely and chronically increases atherosclerosis in mice, yet the mechanisms are unknown. Because lipid synthesis and trafficking are largely under hepatic control, we examined hepatic genes in murine models of acute and chronic oral acrolein exposure.

Methods and results—Changes in hepatic gene expression were examined using a Stereotalk microarray. Acute acrolein feeding modified plasma and hepatic proteins and increased plasma triglycerides within 15 min. By 6h, acrolein altered hepatic gene expression including *Insig1*, *Insig2* and *Hmgcr* genes and stimulated an acute phase response (APR) with up-regulation of serum amyloid A genes (*Saa*) and systemic hypoalbuminemia. To test if decreased HMG-CoA reductase activity could modify acrolein-induced dyslipidemia or the APR, mice were pretreated with simvastatin. Statin treatment, however, did not alter acrolein-induced dyslipidemia or hypoalbuminemia associated with an APR. Few hepatic genes were dysregulated by chronic acrolein feeding in apoE-null mice. These studies confirmed that acute acrolein exposure altered expression of hepatic genes involved with lipid synthesis and trafficking and APR, and thus, indicated a hepatic locus of acrolein-induced dyslipidemia and APR that was independent of HMG CoA-reductase.

Conclusion—Dietary intake of acrolein could contribute to cardiovascular disease risk by disturbing hepatic function.

Keywords

acute phase response; aldehyde; cholesterol; HMG-CoA reductase; lipoproteins

1 Introduction

In addition to being constituents of combustion-derived air and industrial aqueous pollution, aldehydes, such as acrolein, are abundant in foods. More than 300 different aldehydes have been detected in various foods [1, 2]. In most foods and beverages, e.g., beer, rum, and

Address Correspondence To: Daniel J. Conklin, Ph.D., Diabetes and Obesity Center, 580 S. Preston St., Delia Baxter, 404E, University of Louisville, Louisville, KY 40292, Ph: (502) 852-5836, FAX: (502) 852-3663, dj.conklin@louisville.edu.

Conflict of Interest Statement

The authors declare that there are no conflicts of interest.

bread, aldehydes are found at a concentration of 10–20 mg per kg; however, some foods and spices (e.g., cinnamon) contain high concentrations of specific aldehydes. The formation of acrolein in foods, especially cooking oils, is further increased by high temperature cooking, frying and re-heating because frying or heating decreases the *cis*-double bond content of triglycerides and increases the formation of *trans*-unsaturated aldehydes [3]. Overall, we estimate that the maximal daily human consumption of unsaturated aldehydes is nearly 5 mg/kg and the total aldehyde (unsaturated and saturated) consumption is about 7 mg/kg [4].

Recently, we showed that acrolein feeding increases the circulating levels of cholesterol and triglycerides within 24h in mice [5]. Similarly, we have found that chronic acrolein feeding leads to not only a sustained increase in cholesterol levels but that it also increases atherosclerotic lesion progression in apoE-null mice [6]. Because acrolein-induced dyslipidemia appears, in part, as a product of a coordinated acute phase response (APR), whereby plasma lipoprotein levels increase following toxicant exposure or infection [7, 8], we sought to better understand how hepatic gene changes regulate this response. Moreover, we tested whether acute hepatic gene changes were sustained with chronic acrolein feeding in an atherosclerotic murine model. Finally, because acrolein feeding acutely depressed HMG-CoA reductase gene expression (*Hmgcr*), we tested whether suppression of HMGCR activity by statin treatment would alter either acrolein-induced dyslipidemia or the APR. Our results indicated that acute hepatic gene responses to acrolein were extensive and complex wherein APR genes were up-regulated, cholesterol synthesis genes were down-regulated and cholesterol transport genes were dysregulated. The APR response was sustained up to 24h as evidenced by elevated plasma SAA level. Interestingly, acrolein also suppressed plasma leptin levels – a metabolic appetite suppressant. Although only a few hepatic gene changes were identified in the chronic acrolein feeding model, collectively, these findings implicate food-derived aldehyde intake as a potentially important cardiovascular disease risk factor.

2 Materials and methods

Animals

Adult male C57BL/6 and apoE-null mice (8–16 weeks old; Jackson Laboratories, Bar Harbor, ME) were housed and fed water and food *ad libitum* according to animal care guidelines and UofL IACUC-approved protocols. Animals were fed autoclaved standard Rodent Diet 5010® (LabDiet, PMI Nutritional International).

Acrolein Experiments

Because we previously published dose-dependent effects of acrolein (po) in mice, mice were gavage-fed water (control) or acrolein in water (treated) at 5 mg/kg in 100 µl water and euthanized 15 min, 30 min, 60 min, 6h, 12h and 24h after gavage with sodium pentobarbital in distilled water (60 mg/kg i.p. in 0.1 ml). To examine chronic changes, apoE-null mice were gavaged water or acrolein (0.05–1 mg/kg) daily for 8 weeks. Mice were allowed free access to food and water throughout the treatment except when a group was not provided food following gavage treatment (24h fast). To test the beneficial effects of statins, simvastatin (40 or 80 mg/kg, ip; Calbiochem) was administered 1h before acrolein gavage, and mice were euthanized 24h post-treatment [5].

Analytical Measurements

Blood was withdrawn from the right ventricle of pentobarbital-anesthetized mice using 0.2 M Na₄EDTA-coated syringes (25 Ga) and placed in EDTA pre-coated Eppendorf tubes (20 µl/ml blood). Plasma (50 µl) was shipped frozen on dry ice to AssayGate, Inc. (Ijamsville, MD, USA) for analysis of plasma chemokines/cytokines. Total cholesterol, triglycerides and phospholipids in plasma were measured using the Cholesterol CII Enzymatic Kit (Wako

#276-64909), the L-Type TG-H Kit (Wako #432-40201) and Phospholipids B Kit (Wako #990-54009), respectively. Lipids, total protein (Bradford) and albumin (bromocresol green) were measured using calibrated standards with a Cobas Mira Plus 5600 Autoanalyzer [9]. Lipogel and SPE gels were performed with 2 μ l plasma as per manufacturers' directions as previously published [5]. Plasma and liver protein-acrolein adducts were detected as previously published [10].

Values are reported as mean \pm standard error (SEM). For statistical comparison between two groups, Student's unpaired *t*-test was used. For comparing more than two groups, one-way ANOVA and Bonferroni multiple testing correction was used. In both cases, the significance level $\alpha=0.05$ was used.

Hepatic Steroltalk v2 Microarray Analyses

RNA isolation—Hepatic RNA was extracted using Trizol reagent (Invitrogen) according to the manufacturer's protocol, and RNA pellets in ethanol were additionally washed with 75% ethanol, dried and dissolved in 100 μ l of RNase-free water. Nanodrop and Bioanalyzer (Agilent) analyses showed that RNA was of good quality and purity (ratio 260/280 and 260/230 > 1.8).

Steroltalk v2 microarray hybridization—Total RNA from each animal was labeled separately and hybridized with a reference sample. Reference sample was a mixture of all samples used in the experiment. Steroltalk indirect labeling protocol was used to prepare labeled cDNA for hybridizations [11]. Briefly, 20 μ g of total RNA was reverse transcribed using aminoallyl-dUTPs. RNA was hydrolyzed and cDNA purified. Fluorescent dyes were chemically bound to the aminoallyl-cDNA and cDNA was again purified. Samples were labeled with Cy3 and reference with Cy5. Samples were hybridized to the Steroltalk v2 microarrays, in total 28 microarrays were used. Hybridization, washing and scanning of the Steroltalk slides were performed as described previously [12, 13].

Microarray data analysis—Microarray images were analyzed using Array-Pro Analyzer 4.5 (Media Cybernetics, Bethesda, MD, USA). The median feature and local background intensities were extracted together with the estimates of their standard deviation. Raw data was normalized using Orange [14] widget for normalization of focused microarrays. Data were first filtered to exclude spots of low quality: only features with foreground to background ratio higher than 1.5 and coefficient of variation (CV, ratio between standard deviation of the background and the median feature intensity) lower than 0.5 in both channels were considered. \log_2 ratios were normalized using LOWESS fit to spike in control RNAs according to their average intensity [15]. For normalization, the controls were spiked with custom-made Firefly luciferase and commercial Lucidea Universal Scorecard. Data from Lucidea Universal Scorecard ratio controls, for which RNAs were added to each sample RNAs in different concentrations, were adjusted prior to fit of normalization curve according to the ratios between the concentrations.

Pair-wise distances between normalized data of samples were calculated and multi-dimensional scaling (MDS) was used to project the samples into two-dimensional space. Differential expression (DE) of genes was assessed using R/Bioconductor/Limma package [16] by controlling the false discovery rate [17] at level $\alpha=0.05$.

3 Results

Acrolein feeding rapidly modifies plasma and hepatic proteins

Previously, we showed that at 12h post-acrolein oral treatment, plasma hepatic lipase activity (and *Lipc* mRNA) is strongly correlated with plasma hypoalbuminemia ($R^2=0.874$) indicating a relationship between acrolein-induced injury and regulation of dyslipidemia [5]. To better understand the rapidly evolving changes that follow acrolein feeding, time dependent protein-acrolein adducts were measured in both plasma and liver within 15 min after gavage (Fig. 1A,B) and which declined in plasma by 1h. There was a corresponding and significant increase in plasma triglycerides (2-3-fold above background) within 15 min, and this was confirmed by the presence of a VLDL-specific band on Lipogel (Fig. 1C,D). From these data, we infer that hepatic protein-acrolein adducts may be derived, in part, from delivery and uptake of plasma-derived protein-acrolein adducts. Subsequently, at 6h (Fig. 2A,B) and 12h (Fig. 2C,D) post-treatment, plasma samples from water- (control) and acrolein-treated (Acro) mice were electrophoretically-separated for lipoprotein staining (i.e., Lipo-gels; Fig. 2A,C) and plasma protein staining (SPE-gels; Fig. 2B,D). Lipoproteins separated into diffuse high density (HDL), low density (LDL) and very low density lipoprotein (VLDL) bands, and acrolein treatment of 6h resulted in obvious modification of HDL and VLDL/LDL fractions (Fig. 2A,C). Plasma proteins separated into major albumin, alpha, beta and gamma protein bands (see Table 1 for quantification of major lipid and protein fractions), and acrolein treatment by 6h resulted in an obvious decrease in albumin band, a shift in the beta band with a more subtle modification of gamma band (Fig. 2B, D). Modifications in HDL and LDL/VLDL due to acrolein treatment were associated with subtle changes in plasma lipids levels when compared with water controls (Table 1). Acrolein treatment significantly decreased cholesterol, phospholipids albumin and total protein levels by 6h post-treatment (Table 1). These data show that lipoprotein and protein modifications precede the peak of acrolein-induced hypercholesterolemia and hypertriglyceridemia by almost 18h [5].

Hepatic sterol gene alterations in acrolein-treated mice

To gain a better understanding of the relationship between plasma modifications and hepatic sterol and lipoprotein biosynthesis/clearance following oral acrolein exposure, mouse liver RNA from acrolein- and water-treated mice (6h and 12h) was analyzed using the Steroltalk v2 microarrays. The multi-dimensional scaling (MDS) of microarray data exposed clear separation between acute acrolein-treated samples (Figure 3, **top**) and all other (i.e., chronic acrolein-treated and control) samples (Figure 3, **bottom**), which emphasizes the robust nature of rapid genomic changes induced by acrolein. Differential expression (DE) analysis exposed 62 DE genes in the 6h treatment (i.e., 35 up-regulated, 27 down-regulated) and 49 DE genes in the 12h treatment (i.e., 25 up-regulated, 24 down-regulated) (Tables 2, 3).

Cholesterol homeostasis—In the 6h treatment, we observed down-regulation of cholesterol biosynthesis genes, which diminished by 12h. We observed down-regulation of *Insig1* at both time points, yet up-regulation of *Insig2*—both *Insig* proteins are regulators of active SREBP protein. Genes regulating the exchange of cholesterol between liver and plasma were altered. Both mRNA of LDL uptake (*Ldlr*, *Lip1*) and cholesterol efflux via VLDL (*Acat2*) were down-regulated, while *apolipoprotein B* mRNA was up-regulated. The HDL receptor (*Scarb1*), apolipoprotein-A1 (*Apoa1*) and ATP-binding cassette, sub-family A (ABC1), member 1 (*Abca1*) essential for HDL cholesterol trafficking were up-regulated. At 12h, a mRNA for a gene involved in cholesterol excretion to the bile was down-regulated (*Abcg5/8*), while paraoxonase 2 (*Pon2*) mRNA was up-regulated. Bile acid synthesis mRNAs were also disturbed. The classical pathway (*Cyp7a1*, *Cyp8b1*) was down-regulated at 6h, while an alternative pathway using *Cyp39a1* was up-regulated, and yet *Cyp7b1* was

down-regulated. Several genes for bile acid transport from plasma to liver (*Slc10a1*, *Slc01b2* and *Slco1a1*) and liver to bile (*Abcb11*) were down-regulated. Many of these genes are regulated by *Fxr* (*Nr1h4*), which was also down-regulated at 6h. After 12h, the *Cyp17a1* gene of steroid biosynthesis was up-regulated.

Xenobiotic metabolism—Our analyses showed that acrolein up-regulated the *Cyp2b* family at 6h and 12h yet down-regulated several other members of the xenobiotic metabolizing *Cyp* families (e.g., *Cyp2a4*, *Cyp1a2*, *Cyp2c40*, *Cyp2j5* and *Cyp3a25*). Modest down-regulation of nuclear receptor constitutive androstane receptor, *Car* (*Nr1i3*), gene at 6h as well as several other nuclear receptor family members was observed. The transporter gene *Abcc1* (*Mrp1*) was modestly up-regulated at both 6h and 12h.

Acute Phase Response Genes—The major up-regulated acute phase response (APR) genes were the serum amyloid A genes (*Saa*), but also up-regulated were *Orrm1*, *Fgb*, *Hpxn*, *Apcs* and *C4bp*. The adiponectin receptor was down-regulated at 6h, whereas adiponectin gene expression (*Adipoq*) increased at 12h. Heme synthesis gene (*Alas1*) was down-regulated at 6h. Some circadian rhythm genes were up-regulated (*Clock*, *Cry1*, *Crem*) at 6h and down-regulated (*Nr1d2*) at 12h.

Glucose and fatty acid regulatory genes—Glucose homeostasis genes were changed; namely genes of gluconeogenesis (*Pck1*) and transport of glucose (*Slc2a4* – *Glut4*) were up-regulated. Other genes involved in glucose regulation (*Foxo1*, *Ppp1r3c*, *Crem*, *Sirt1*) were up-regulated at 6h. The fatty acid synthesis gene (*Fasn*) was down-regulated, but a gene (*Scd1*) of the unsaturated fatty acid pathway was up-regulated at 6h.

Inflammation markers

At 24h post-oral acrolein, various plasmatic factors including APR reactants (CRP, fibrinogen and SAA), cytokines (IL-1 β , IL-6, IL-10, TNF- α) and chemokines (ICAM-1, VEGF, leptin) were measured by commercial vendor (Table 4). As expected, SAA level was significantly increased by acrolein treatment as were VEGF and IL-6 levels. Surprisingly, fibrinogen (not significantly), leptin and sICAM-1 levels were lower in acrolein-treated mice than in water controls. These data confirm that, at least for SAA, hepatic gene changes at 6h and 12h (Table 2) are positively correlated with systemic protein changes evincing the predictive utility of the Steroltalk v2 microarray.

Effects of simvastatin

Because statins are effective inhibitors of HMGCR activity and have multiple beneficial effects in extra-hepatic tissues (e.g., pleiotropic effects), we tested the potential benefits of statin pretreatment on plasma lipids, the APR and organ injury. Previously, we had shown that simvastatin-pretreated mice are not protected from acrolein-induced dyslipidemia at 24h post-exposure [5]. In the current study, using 2 different statin doses (40 and 80 mg/kg), simvastatin pretreatment neither affected acrolein-induced dyslipidemia nor hypoalbuminemia (Tables 5, 6). Moreover, simvastatin failed to protect against acrolein-induced increase in stomach weight/body weight ratio (data not shown) indicating that the effects of acrolein do not depend upon HMGCR activity in either hepatic or extra-hepatic tissues further supporting that genetic targets of acrolein other than *Hmgcr* are likely more important (e.g., *Lipc*).

Effect of fasting on acrolein-induced dyslipidemia

Because acrolein treatment decreased leptin levels (appetite suppressant) and increased stomach weight, we tested the importance of food intake as a modifier of acrolein action.

Previously, we showed that post-treatment fasting did not significantly alter acrolein-induced dyslipidemia (water+fasting: cholesterol, 83 ± 4 mg/dL; triglycerides, 40 ± 4 mg/dL; ACRO+fasting: cholesterol, 103 ± 6 mg/dL; triglycerides, 132 ± 25 mg/dL; $n=5,5$, $p<0.05$)[5], yet we did not quantify whether fasting altered specific cholesterol fraction, peripheral organ injury or hypoalbuminemia. Post-treatment fasting significantly decreased overall stomach weight compared with *ad libitum*-fed mice (data not shown), but empty stomach weight was significantly greater in acrolein-fed mice ($+149\pm 9\%$ controls; $n=5, 5$) compared with controls. Similarly, fasting did not prevent hypoalbuminemia (albumin: control: 31.88 ± 0.08 g/L; acrolein: 19.26 ± 0.05 g/L; $p<0.05$). Under fasting conditions, acrolein significantly increased LDL cholesterol (control: 12.96 ± 0.64 mg/dL; acrolein: 35.46 ± 2.87 mg/dL; $p<0.05$) but not HDL cholesterol (control: 61.06 ± 3.30 mg/dL; acrolein: 56.92 ± 2.64 mg/dL). These data suggest a complex interplay between direct protein-acrolein adduct formation, systemic injury and the coordinated hepatic-driven responses that are dependent on metabolic state and feeding behavior.

Chronic acrolein treatment of apoE-null mice – 8 week study

In the chronic experiment, analysis of hepatic mRNA from apoE-null mice fed acrolein (2.5 mg/kg/d for 8 weeks) yielded only 2 modestly up-regulated genes (i.e., *Apoc1*, *Abcb1a*) (data not shown). This result was in accordance with the MDS analysis, wherein the 8-weeks treated samples were grouped together and were located close to the water control samples from both chronic and acute experiments than to the acute acrolein samples (see Fig. 3). We recently published that an 8-week acrolein (2.5 mg/kg/d) treatment accelerated atherosclerosis, most likely *via* platelet activation and/or dyslipidemia [6]. We measured plasma lipids levels in apoE-null mice treated with lower doses of acrolein (0.05, 0.1, 0.5, 1 mg/kg, p.o.). Acrolein feeding significantly increased the levels of cholesterol, phospholipids and triglycerides in mice treated with 0.1 or 0.5 mg/kg doses (Fig. 4), however, no dose dependence, was observed.

4 Discussion

In this report we present a refined time course relationship between acute oral exposure to acrolein, showing rapid modification of plasma and hepatic proteins, and subsequent alterations in hepatic regulatory genes that orchestrate acrolein-induced dyslipidemia and APR in mice. We found that acrolein down-regulates *Hmgcr* by 6h likely *via* complex changes in SREBP, *Insig1* and *Insig2*, indicating that acrolein action likely begins with transcriptional changes in sterol regulatory factors. These findings highlight the complexity of acrolein action and demonstrate that exposure to food-derived aldehydes could be an important contributor to cardiovascular disease risk.

Role of plasma protein modifications

In our previous study we found that acrolein-induced lipoprotein modifications occurs over 6–24h of exposure [5], whereas herein we show that there are immediate acrolein-induced modifications in plasma and hepatic proteins (along with an abrupt yet modest increase in triglycerides). Because of a brief lag period between the peaks of plasma and hepatic protein modifications, we reason that acrolein-modified proteins could be distributed to hepatic sites. Similarly, Li et al., (2004) have reported the appearance of acrolein-modified plasma proteins of 100, 31, and 29 kDa at 1h after oral acrolein exposure in Sprague-Dawley rats (9.2 mg/kg)[18]. Although we also showed that modified lipoproteins circulate for almost 3 days in the plasma [5], acrolein-modified proteins are rapidly removed (decreasing by 1h) from the circulation and perhaps these are removed by the liver (e.g., one major M_r band, 150 kDa, is present in both the plasma and the liver) as well as at other sites. In a previous study, we identified an acrolein-modified ≈ 150 kDa protein as Complement Factor H using

2-D electrophoresis and MALDI-TOF analysis [19]. Whether or not these modified proteins are mechanistically linked to subsequent hepatic gene changes at 6h and 12h or dyslipidemia is unknown and will serve as a focus of follow-up studies.

Hepatic gene changes orchestrate acrolein-induced dyslipidemia

Our previous analyses of limited hepatic genes changes implicated a locus of acrolein action *via* down-regulation of both hepatic lipase (*Lipc*) and *Ldlr* gene mRNAs at 6h post-treatment [5]. Our current study complements and extends those measurements to implicate an important role of the upstream sterol synthesis regulators, Insulin-induced genes 1 and 2 (*Insig1* and *Insig2*), that control cholesterol biosynthetic and trafficking pathways *via* interactions with sterol regulatory element-binding protein (SREBP). Acrolein feeding down-regulates *Insig1* but up-regulates *Insig2* at both 6h and 12h time points (see Tables 3, 4). *Insig* proteins anchor SREBP and SREBP cleavage activating protein (SCAP) in the ER in a cholesterol-dependent manner, and when cholesterol is low, INSIG is degraded and SREBP translocates to the nucleus to activate transcription [20]. It is known that SREBP promotes *Hmgcr* and *Insig1* transcription, yet both these genes are down-regulated by acrolein. However, *Insig2* is believed to play a more important role than *Insig1* in the liver [20]. As cholesterol is the primary negative feedback regulator of SREBP by binding to SCAP [21], these gene data are consistent with our previous finding that acrolein significantly increases hepatic cholesterol level at 6h post-treatment [5], and thus, initiates a negative feedback response. Similarly, rats fed thermally-oxidized sunflower oil (~18 ml/kg; 6d; significantly elevated carbonyl content of ~32-fold) had significantly lower hepatic *Hmgcr* and *Ldlr* mRNA levels compared with rats fed fresh sunflower oil [22]. Thus, carbonyl-containing compounds, such as aldehydes, can dramatically alter the hepatic transcriptome perhaps through inducing ER stress as demonstrated for acrolein in other tissues [23].

It is not clear how acrolein increases hepatic cholesterol while down-regulating *Hmgcr* and *Insig1* mRNAs, but it appears this is not HMGCR activity-dependent. We tested 2 doses of simvastatin (40 and 80 mg/kg) and statin treatment neither blocked acrolein-induced dyslipidemia nor acrolein-induced gastric injury nor hypoalbuminemia. Collectively, these data indicate that acrolein feeding induces a coordinated transcriptionally-regulated decrease in cholesterol biosynthesis genes. Thus, we think that aldehydes in foods and beverages [24] could, in general, suppress hepatic cholesterol biosynthesis and uptake genes *via* a common transcriptional mechanism dependent on negative feedback. This idea is partially supported by the modifying effect of fasting on acrolein-induced dyslipidemia, which led to an increase in plasma cholesterol in the LDL but not the VLDL fraction [5].

Hepatic Cyp genes and xenobiotic metabolism

Not surprisingly, numerous *Cyp* genes were dysregulated by acrolein treatment at 6h and 12h, but the 2b group of *Cyp* genes is consistently up-regulated at both 6h and 12h. These genes are classified as xenobiotic metabolism genes and we showed previously that indeed CYP2B and 3A family member proteins catalyze unsaturated aldehyde oxidation to carboxylic acid [25]. The *Cyp2b* family genes are induced by compounds that activate the constitutive androstane receptor (CAR), and obesity is known to ameliorate expression of these genes [26]. Similarly, other *Cyp2* and *Cyp3* family genes are down-regulated by interleukins and inflammation [27, 28], and thus, these results suggest that acrolein feeding regulates these genes in a manner similar to the effects of inflammation or obesity. The role of AP1 proteins in down-regulation of these genes has been suggested by Blouin and co-workers [26, 27]. Because these proteins, in general, are likely part of a larger contingent of protective enzymes that are up-regulated in liver following xenobiotic exposure, amelioration of their expression may enhance liver cell toxicity. Paradoxically, the

suppression of CAR expression is in contrast to the increase in *Cyp2b* family observed and different from the observations of Blouin and coworkers who observed suppression of *Cyp2b* family member expression in the obese mouse [26, 27]. Induction of *Cyp2b* in murine liver by agents like phenobarbital results in increased mRNA and protein levels, so the contradiction suggests that another mode of regulation of this gene also occurs, such as phosphorylation by protein kinases, such as AMP kinase [29]. Because of the specific focus of the Steroltalk microarray on sterol metabolism genes, we did not measure many phase II xenobiotic metabolism genes (e.g., GSTs, aldehyde reductases), which could be up-regulated in apoE-null mice by chronic acrolein feeding, and thus, could have diminished the sterol signal for these acute gene changes.

Similarly, many of the CYPs involved in bile acid synthesis are suppressed during inflammation [30]. Specifically, LPS suppresses bile acid formation by specifically decreasing expression of *Cyp7a* and *Cyp27a*, the rate limiting enzymes in conversion of cholesterol to bile acids. TNF- α and IL-1 have been shown to decrease *Cyp27a* levels in HepG2 cells demonstrating direct regulation of these genes in mice and humans. This decrease is also observed in our study of acrolein action, which further supports that acrolein feeding activates an inflammatory process.

Hepatic gene changes reflect an acute phase response (APR)

Acrolein induces an APR as evidenced by elevated SAA and sustained hypoalbuminemia up to 24h. These changes appear to be a consequence of up-regulated hepatic *Saa* genes. Other APR genes were also up-regulated including fibrinogen (*Fgb*) and serum amyloid P (*Apcs*), although the former change did not result in increased plasma fibrinogen (measured at 24h), and unexpectedly, plasma fibrinogen is significantly lower in acrolein-treated mice compared with water controls. This discrepancy could be explained because acrolein exposure (feeding or inhalation) increases platelet activation, and thus, an increased clotting (perhaps in stomach wall) could effectively lower the plasma level of fibrinogen due to platelet-fibrinogen interactions [31]. Additional evidence for a vascular inflammatory event includes significant changes in plasma sICAM-1, VEGF and IL-6 (see Table 4), which could also provide additional stimuli for hepatic gene changes.

5 Conclusions

Acrolein and cardiovascular disease (CVD) risk

Exposure to acrolein and related aldehydes is a major health concern [32, 33]. Environmental sources of acrolein include industrial emissions, automobile exhaust, combustion sources and consumables (foods and beverages)[34]. Aldehydes such as acrolein, crotonaldehyde and hexenal are natural constituents of several foods and spices and their concentration in food and drink is increased upon oxidation, brewing, heating, cooking and frying (see summary in Conklin et al., 2011)[19]. Moreover, aldehyde exposure *via* ingestion, including acrolein, is likely to exceed that due to inhalation alone [4]. Hence our observation that oral intake of acrolein induces dyslipidemia in mice raises important issues regarding pollutants and constituents of diet and cardiovascular disease risk. Although the human risk due to acrolein exposure remains to be assessed, the results of the current study suggest the possibility that exposure to acrolein or similarly reactive constituents of foods could contribute to sustained dyslipidemia and inflammation that increase CVD risk.

Acknowledgments

This work was supported in part by grants from NIH (ES11860, ES17260), DOD, EPA, Philip Morris USA Inc. and by Philip Morris International, and STEROLTALK project, funded by the European Community as contract No. LSHG-CT-2005-512096 under the FP6 Programme. Research described in this article, in part, was conducted under

contract to the Health Effects Institute (HEI), with funding from the Federal Highway Administration under Grant Agreement No. DTFH61-09-G-00010. Any opinions, findings, and conclusions or recommendations expressed in this publication are those of the author(s) and do not necessarily reflect the view of HEI or the Federal Highway Administration. We thank D. Young and E. Steinmetz for technical assistance.

Abbreviations

| | |
|--------------|---|
| APR | acute phase response |
| DE | differentially expressed |
| HDL | high density lipoprotein |
| HMGCR | HMG-CoA reductase |
| LDL | low density lipoprotein |
| MDS | multidimensional scaling |
| SAA | serum amyloid A |
| SPE | serum protein electrophoresis |
| SREBP | sterol regulatory element-binding protein |
| VLDL | very low density lipoprotein |

References

1. Feron VJ, Til HP, de Vrijer F, Woutersen RA, et al. Aldehydes: occurrence, carcinogenic potential, mechanism of action and risk assessment. *Mutation Research*. 1991; 259:363–385. [PubMed: 2017217]
2. Ghilarducci DP, Tjeerdema RS. Fate and effects of acrolein. *Rev. Environ. Contam Toxicol*. 1995; 144:95–146. [PubMed: 8599034]
3. Fullana A, Carbonell-Barrachina AA, Sidhu S. Comparison of volatile aldehydes present in the cooking fumes of extra virgin olive, olive, and canola oils. *J. Agric. Food Chem*. 2004; 52:5207–5214. [PubMed: 15291498]
4. Wang GW, Guo Y, Vondriska TM, Zhang J, et al. Acrolein consumption exacerbates myocardial ischemic injury and blocks nitric oxide-induced PKCepsilon signaling and cardioprotection. *J. Mol. Cell Cardiol*. 2008; 44:1016–1022. [PubMed: 18468618]
5. Conklin DJ, Barski OA, Lesgards JF, Juvan P, et al. Acrolein consumption induces systemic dyslipidemia and lipoprotein modification. *Toxicol Appl Pharmacol*. 2010; 243:1–12. [PubMed: 20034506]
6. Srivastava S, Sithu SD, Vladykovskaya E, Habertzettl P, et al. Oral exposure to acrolein exacerbates atherosclerosis in apoE-null mice. *Atherosclerosis*. 2011
7. Khovidhunkit W, Kim MS, Memon RA, Shigenaga JK, et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. *J. Lipid Res*. 2004; 45:1169–1196. [PubMed: 15102878]
8. Tous M, Ribas V, Ferre N, Escola-Gil JC, et al. Turpentine-induced inflammation reduces the hepatic expression of the multiple drug resistance gene, the plasma cholesterol concentration and the development of atherosclerosis in apolipoprotein E deficient mice. *Biochimica et Biophysica Acta*. 2005; 1733:192–198. [PubMed: 15863366]
9. Conklin DJ, Habertzettl P, Prough RA, Bhatnagar A. Glutathione-S-transferase P protects against endothelial dysfunction induced by exposure to tobacco smoke. *Am. J. Physiol Heart Circ. Physiol*. 2009; 296:H1586–H1597. [PubMed: 19270193]
10. Conklin DJ, Habertzettl P, Lesgards JF, Prough RA, et al. Increased sensitivity of glutathione S-transferase P-null mice to cyclophosphamide-induced urinary bladder toxicity. *J Pharmacol Exp Ther*. 2009; 331:456–469. [PubMed: 19696094]

11. Simoncic M, Rezen T, Juvan P, Rozman D, et al. Obesity resistant mechanisms in the Lean polygenic mouse model as indicated by liver transcriptome and expression of selected genes in skeletal muscle. *BMC Genomics*. 2011; 12:96. [PubMed: 21291556]
12. Rezen T, Juvan P, Fon TK, Kuzman D, et al. The Sterolgene v0 cDNA microarray: a systemic approach to studies of cholesterol homeostasis and drug metabolism. *BMC Genomics*. 2008; 9:76. [PubMed: 18261244]
13. Rezen T, Tamasi V, Lovgren-Sandblom A, Bjorkhem I, et al. Effect of CAR activation on selected metabolic pathways in normal and hyperlipidemic mouse livers. *BMC Genomics*. 2009; 10:384. [PubMed: 19691840]
14. Demšar, J.; Zupan, B.; Leban, G. University of Ljubljana. Ljubljana: Slovenia; 2004.
15. Cleveland WS, Devlin SJ. Locally-Weighted Regression: An Approach to Regression Analysis by Local Fitting. *Journal of the American Statistical Association*. 1988:596–610.
16. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. *Stat.Appl.Genet.Mol.Biol*. 2004; 3 Article3.
17. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *Journal of the Royal Statistical Society*. 1995; Series B:289–300.
18. Li H, Wang J, Kaphalia B, Ansari GA, Khan MF. Quantitation of acrolein-protein adducts: potential biomarker of acrolein exposure. *J.Toxicol.Environ.Health A*. 2004; 67:513–524. [PubMed: 14742096]
19. Conklin, DJP.; Haberzettl, J.; Lee, J.; Srivastava, S. *Environmental Cardiology: Pollution and Heart Disease*. Bhatnagar, A., editor. London, England: Royal Society of Chemistry; 2011. p. 390
20. Radhakrishnan A, Ikeda Y, Kwon HJ, Brown MS, Goldstein JL. Sterol-regulated transport of SREBPs from endoplasmic reticulum to Golgi: oxysterols block transport by binding to Insig. *Proc.Natl.Acad.Sci.U.S.A*. 2007; 104:6511–6518. [PubMed: 17428920]
21. Espenshade PJ, Hughes AL. Regulation of sterol synthesis in eukaryotes. *Annu.Rev.Genet*. 2007; 41:401–427. [PubMed: 17666007]
22. Koch A, Konig B, Spielmann J, Leitner A, et al. Thermally oxidized oil increases the expression of insulin-induced genes and inhibits activation of sterol regulatory element-binding protein-2 in rat liver. *J.Nutr*. 2007; 137:2018–2023. [PubMed: 17709436]
23. Haberzettl P, Vladykovskaya E, Srivastava S, Bhatnagar A. Role of endoplasmic reticulum stress in acrolein-induced endothelial activation. *Toxicol Appl Pharmacol*. 2009; 234:14–24. [PubMed: 18951912]
24. Vesely P, Lusk L, Basarova G, Seabrooks J, Ryder D. Analysis of aldehydes in beer using solid-phase microextraction with on-fiber derivatization and gas chromatography/mass spectrometry. *J.Agric.Food Chem*. 2003; 51:6941–6944. [PubMed: 14611150]
25. Amunom I, Stephens LJ, Tamasi V, Cai J, et al. Cytochromes P450 catalyze oxidation of alpha,beta-unsaturated aldehydes. *Arch.Biochem.Biophys*. 2007; 464:187–196. [PubMed: 17599801]
26. Zannikos PN, Bandyopadhyay AM, Robertson LW, Blouin RA. Cytochrome P450 2B enzyme induction defect after 2,2',4,4',5,5'-hexachlorobiphenyl treatment in the fa/fa Zucker rat. *J Pharmacol Exp Ther*. 1994; 268:1565–1570. [PubMed: 8138968]
27. Roe AL, Warren G, Hou G, Howard G, et al. The effect of high dose endotoxin on CYP3A2 expression in the rat. *Pharm Res*. 1998; 15:1603–1608. [PubMed: 9794504]
28. Aitken AE, Morgan ET. Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes. *Drug Metab Dispos*. 2007; 35:1687–1693. [PubMed: 17576808]
29. Rencurel F, Foretz M, Kaufmann MR, Stroka D, et al. Stimulation of AMP-activated protein kinase is essential for the induction of drug metabolizing enzymes by phenobarbital in human and mouse liver. *Mol Pharmacol*. 2006; 70:1925–1934. [PubMed: 16988011]
30. Memon RA, Moser AH, Shigenaga JK, Grunfeld C, Feingold KR. In vivo and in vitro regulation of sterol 27-hydroxylase in the liver during the acute phase response. potential role of hepatocyte nuclear factor-1. *J Biol Chem*. 2001; 276:30118–30126. [PubMed: 11406622]
31. Sithu SD, Srivastava S, Siddiqui MA, Vladykovskaya E, et al. Exposure to acrolein by inhalation causes platelet activation. *Toxicol Appl Pharmacol*. 2010; 248:100–110. [PubMed: 20678513]

32. Committee on, A. Formaldehyde and other aldehydes. Washington D.C.: National Academy Press; 1981.
33. Bhatnagar A. Cardiovascular pathophysiology of environmental pollutants. *Am.J.Physiol Heart Circ.Physiol.* 2004; 286:H479–H485. [PubMed: 14715496]
34. Stevens JF, Maier CS. Acrolein: sources, metabolism, and biomolecular interactions relevant to human health and disease. *Mol.Nutr.Food Res.* 2008; 52:7–25. [PubMed: 18203133]




Figure 1. Acrolein-induced protein and lipoprotein modifications in vivo

At 15, 30 and 60 min post-treatment, plasma and organ samples from water (control; 30 min only; n=2) and acrolein- (ACRO; n=2) treated mice were separated electrophoretically by SDS-PAGE. Western blots were developed using anti-protein-acrolein antibodies (A, B). Alternatively, the plasma proteins were separated on Lipo-gels and stained for cholesterol (C). Plasma lipids were quantified at each time point (D). Lipoproteins separated into diffuse bands corresponding to high density (HDL), low density (LDL) and very low density lipoprotein (VLDL).




Figure 2. Acrolein-induced delayed protein and lipoprotein modifications in vivo
 At 6h (**A, B**) and 12h (**C, D**) post-treatment, plasma samples from water (control) and acrolein (Acro) treated mice were electrophoretically separated for measuring changes in lipoprotein (i.e., Lipo-gels; **A, C**) and plasma protein (SPE-gels; **B, D**). Lipoproteins separated into diffuse bands corresponding to high density (HDL), low density (LDL) and very low density lipoprotein (VLDL). Plasma proteins separated into major bands that correspond to albumin, alpha, beta and gamma protein bands (see Table 1 for quantification of major lipid and protein fractions; n=3-4).




Figure 3. Multi-dimensional scaling (MDS) analysis of microarray results

MDS was used to project the samples into two-dimensional space using top 80 probes. The 8-week acrolein treatment (A8w) had minimal effect on hepatic gene expression as detected by the Steroltalk v2 microarray. However, both 6h (A6h) and 12h (A12h) acrolein-treated samples were grouped away from respective water-treated (W) samples consistent with statistically significant alterations in over 50 differentially-expressed genes (see Tables 3, 4).




Figure 4. Effects of chronic acrolein on plasma lipids in apoE-null mice
 Plasma lipids were measured in water- and acrolein- (0.05, 0.1, 0.5, 1 mg/kg/day, po) treated apoE-null mice after 8 weeks of treatment. *, significant difference between control and acrolein treatments ($p < 0.05$; one-way ANOVA with Bonferroni correction).

Table 1

Early time course of acrolein (ACRO)-induced dyslipidemia and hypoalbuminemia.

| <u>Parameter</u> | <u>6h</u> | | <u>12h</u> | |
|----------------------------|----------------------|-----------------|--------------------|-----------------|
| | <u>Control (3-4)</u> | <u>ACRO (4)</u> | <u>Control (4)</u> | <u>ACRO (4)</u> |
| Cholesterol ¹ | 71.8±1.0 | 52.6±5.9* | 66.1±3.7 | 84.4±4.6* |
| Phospholipids ¹ | 142.4±1.7 | 76.0±8.1* | 123.9±6.5 | 150.1±18.7* |
| Triglycerides ¹ | 62.6±29.0 | 52.2±9.0 | 35.9±10.5 | 167.9±56.2* |
| Albumin ² | 29.1±1.1 | 13.6±1.3* | 30.1±0.5 | 12.9±0.5* |
| Protein ² | 43.2±1.0 | 23.0±2.0* | 45.1±1.0 | 23.6±0.5* |

Adult C57BL/6 mice were gavage fed either water (Control) or acrolein (ACRO; 5 mg/kg) and changes in the indicated plasma constituents were measured at either 6h or 12h post-treatment. Values = mean ± S.E.; Units:

¹[mg/dl],

²[g/L]; (n), number of mice per group;

* significant difference between ACRO treatment and respective Control values ($p < 0.05$).

Table 2

Up-regulated differentially expressed hepatic genes in acrolein-treated mice using the Steroltalk v2 microarray.

| Gene Symbol | Gene Description | Log ₂ ratio 6h | Log ₂ ratio 12h | GenBank Accession |
|---|---|---------------------------------|----------------------------------|----------------------|
| Xenobiotic metabolism | | | | |
| <i>Cyp2b10</i> | Cytochrome P450, family 2, subfamily b, polypeptide 10 | 2.26 | 1.57 | AK028103 |
| <i>Cyp2b9</i> | Cytochrome P450, family 2, subfamily b, polypeptide 9 | 2.25 | 1.60 | NM_010000 |
| <i>Cyp2b13</i> | Cytochrome P450, family 2, subfamily b, polypeptide 13 | 2.14 | 1.55 | NM_007813 |
| <i>Abcc1</i> | ATP-binding cassette, sub-family C (CFTR/MRP), member 1 | 0.50 | 0.49 | NM_008576 |
| Cholesterol, bile acid and steroid homeostasis | | | | |
| <i>Cyp17a1</i> | Cytochrome P450, family 17, subfamily a, polypeptide 1 | NO | 1.01 | NM_007809 |
| <i>Insig2</i> | Insulin induced gene 2 | 2.47 | 1.50 | BC023874 |
| <i>Abca1</i> | ATP-binding cassette, sub-family A (ABC1), member 1 | 1.27 | 1.38 | NM_013454 |
| <i>Cyp39a1</i> | Cytochrome P450, family 39, subfamily a, polypeptide 1 | 0.92 | 0.62 | AF237981 |
| <i>Apoa1</i> | Apolipoprotein A-I | 0.73 | 0.86 | NM_009692 |
| <i>Scarb1</i> | Scavenger receptor class B, member 1 | 0.60 | NO | NM_016741 |
| <i>ApoB</i> | Apolipoprotein B | 0.49 | NO | XM_137955 |
| <i>Pon2</i> | Paraoxonase 2 | 0.36 | NO | NM_183308 |
| Acute Phase Response and Serum proteins | | | | |
| <i>Saa2</i> | Serum amyloid A 2 | 5.32 | 5.90 | BC024606 |
| <i>Saa1</i> | Serum amyloid A 1 | 5.22 | 5.82 | BC087933 |
| <i>Saa3</i> | Serum amyloid A 3 | 4.70 | 5.35 | BC055885 |
| <i>Orm1</i> | Orosomucoid 1 | 1.35 | 1.20 | BC012725 |
| <i>Fgb</i> | Fibrinogen, B beta polypeptide | 1.22 | 1.85 | NM_181849 |
| <i>Hpxn</i> | Hemopexin | 0.95 | 0.86 | BC019901 |
| <i>Apcs</i> | Serum amyloid P-component | NO | 2.27 | BC061125 |
| <i>C4bp</i> | Complement component 4 binding protein | NO | 1.32 | NM_007576 |
| Cell signaling | | | | |
| <i>Egr-1</i> | Early growth response 1 | 2.62 | 2.44 | M20157 |
| <i>Foxo1</i> | Forkhead box O1 | 1.88 | NO | NM_019739 |
| <i>Ppp1r3c</i> | Protein phosphatase 1, regulatory (inhibitor) subunit 3C | 1.71 | NO | NM_016854 |
| <i>Stat3</i> | Signal transducer and activator of transcription 3 | 1.12 | 1.06 | BC003806 |
| <i>Hnf4a</i> | Hepatic nuclear factor 4, alpha | 0.90 | NO | NM_008261 |
| <i>Fos</i> | FBJ osteosarcoma oncogene | 0.83 | NO | NM_010234 |
| <i>Crem</i> | CAMP responsive element modulator | 0.82 | NO | M60285 |
| <i>Sp1</i> | Trans-acting transcription factor 1, Specificity protein 1 | 0.60 | NO | AF062566 |
| <i>Clock</i> | Circadian locomotor output cycles kaput | 0.50 | NO | AF000998 |
| <i>Sirt1</i> | Sirtuin 1, silent mating type information regulation 2, homolog 1 | 0.46 | NO | NM_019812 |
| <i>Cry1</i> | Cryptochrome 1 (photolyase-like) | 0.44 | NO | NM_007771 |
| <i>Ppargc1a</i> | Peroxisome proliferative activated receptor, gamma, coactivator 1 alpha | 0.41 | NO | NM_008904 |

| Gene Symbol | Gene Description | Log ₂ ratio 6h | Log ₂ ratio 12h | GenBank Accession |
|---------------------------------|---|---------------------------------|----------------------------------|----------------------|
| Xenobiotic metabolism | | | | |
| <i>Mapk8</i> | Mitogen activated protein kinase 8 | 0.27 | NO | BC053027 |
| <i>Adipoq</i> | Adiponectin, C1Q and collagen domain containing | NO | 0.57 | BC028770 |
| <i>P53</i> | Transformation related protein 53 | NO | 0.41 | BC005448 |
| Other metabolic pathways | | | | |
| <i>Scd1</i> | Stearoyl-Coenzyme A desaturase 1 | 0.97 | NO | BC007474 |
| <i>Actb</i> | Actin, beta, cytoplasmic | 0.67 | 0.67 | NM_007393 |
| <i>Actb</i> | Actin, beta, cytoplasmic | 0.63 | 0.59 | NM_007393 |
| <i>Pck1</i> | Phosphoenolpyruvate carboxykinase 1, cytosolic | 0.55 | NO | BC037629 |
| <i>Slc2a4</i> | Solute carrier family 2 (facilitated glucose transporter), member 4 | 0.46 | NO | BC014282 |
| <i>Uap1</i> | UDP-N-acetylglucosamine pyrophosphorylase 1 | NO | 0.77 | BC016406 |
| <i>TUBB2B</i> | Tubulin, beta 2B | NO | 1.04 | NM_001069 |

Probability of type I error $\alpha=0.05$. NO – no differential expression was observed.

Table 3

Down-regulated differentially expressed hepatic genes in acrolein-treated mice using the Steroltalk v2 microarray.

| GeneSymbol Xenobiotic metabolism | Gene Description | Log ₂ ratio 6h | Log ₂ ratio 12h | GenBank Accession |
|--|--|---------------------------------|----------------------------------|----------------------|
| <i>Cyp2a4</i> | Cytochrome P450, family 2, subfamily a, polypeptide 5 | -0.97 | -1.36 | BC011233 |
| <i>Cyp1a2</i> | Cytochrome P450, family 1, subfamily a, polypeptide 2 | NO | -0.80 | NM_009993 |
| <i>Cyp2c40</i> | Cytochrome P450, family 2, subfamily c, polypeptide 40 | NO | -0.71 | NM_010004 |
| <i>Cyp2j5</i> | Cytochrome P450, family 2, subfamily j, polypeptide 5 | NO | -0.52 | NM_010007 |
| <i>Cyp3a25</i> | Cytochrome P450, family 3, subfamily a, polypeptide 25 | NO | -0.42 | BC028855 |
| Cholesterol biosynthesis and regulation | | | | |
| <i>Hmgcr</i> | 3-hydroxy-3-methylglutaryl-Coenzyme A reductase | -1.49 | NO | NM_008255 |
| <i>Insig1</i> | Insulin induced gene 1 | -1.16 | -1.27 | NM_153526 |
| <i>Mvd</i> | Mevalonate (diphospho) decarboxylase | -1.14 | NO | NM_138656 |
| <i>Fdft1</i> | Farnesyl diphosphate farnesyl transferase 1, Squalene synthase | -1.10 | NO | NM_010191 |
| <i>Acas2</i> | Acyl-CoA synthetase short-chain family member 2 | -1.03 | -1.45 | NM_019811 |
| <i>Sc4mol</i> | Sterol-C4-methyl oxidase-like | -1.02 | NO | NM_025436 |
| <i>Hmgcs1</i> | 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 | -0.83 | NO | NM_145942 |
| <i>Sc5d</i> | Sterol-C5-desaturase homolog | -0.59 | -0.60 | BC024132 |
| Cholesterol, bile acid, steroid homeostasis | | | | |
| <i>Cyp8b1</i> | Cytochrome P450, family 8, subfamily b, polypeptide 1 | -1.51 | -1.49 | NM_010012 |
| <i>Ldlr</i> | Low density lipoprotein receptor | -1.25 | -0.63 | BC019207 |
| <i>SLC10A1</i> | Solute carrier family 10 (sodium/bile acid cotransporter family), member 1 | -0.96 | -0.75 | BC094023 |
| <i>Slco1b2</i> | Solute carrier organic anion transporter family, member 1b2 | -0.88 | -0.80 | NM_020495 |
| <i>Cyp7a1</i> | Cytochrome P450, family 7, subfamily a, polypeptide 1 | -0.71 | NO | NM_007824 |
| <i>Slco1a1</i> | Solute carrier organic anion transporter family, member 1a1 | -0.70 | -0.66 | AY195868 |
| <i>Lip1</i> | Lysosomal acid lipase 1 | -0.60 | NO | NM_021460 |
| <i>Acat2</i> | Acetyl-Coenzyme A acetyltransferase 2 | -0.54 | -0.81 | NM_009338 |
| <i>Abcb11</i> | ATP-binding cassette, sub-family B (MDR/TAP), member 11 | -0.32 | -0.53 | NM_021022 |
| <i>Abcg5</i> | ATP-binding cassette, sub-family G (WHITE), member 5 | NO | -0.57 | NM_031884 |
| <i>Abcg8</i> | ATP-binding cassette, sub-family G (WHITE), member 8 | NO | -0.43 | NM_026180 |
| <i>Cyp7b1</i> | Cytochrome P450, family 7, subfamily b, polypeptide 1 | NO | -1.06 | BC038810 |
| Cell signaling | | | | |
| <i>Nr1i3</i> | Nuclear receptor subfamily 1, group I, member 3 | -0.93 | NO | NM_009803 |
| <i>Nr1h4</i> | Nuclear receptor subfamily 1, group H, member 4 | -0.89 | NO | NM_009108 |
| <i>Cebpa</i> | CCAAT/enhancer binding protein (C/EBP), alpha | -0.83 | -0.63 | BC028890 |
| <i>Adipor2</i> | Adiponectin receptor 2 | -0.77 | NO | NM_197985 |
| <i>Nr2f2</i> | Nuclear receptor subfamily 2, group F, member 2 | -0.77 | -0.42 | NM_009697 |
| <i>Pcaf</i> | P300/CBP-associated factor | -0.49 | -0.62 | BC082581 |
| <i>Nr1d2</i> | Nuclear receptor subfamily 1, group D, member 2 | NO | -0.63 | NM_011584 |
| <i>Prkaa1</i> | Protein kinase, AMP-activated, alpha 1 catalytic subunit | NO | -0.27 | NM_001013367 |

| GeneSymbol Xenobiotic metabolism | Gene Description | Log ₂ ratio 6h | Log ₂ ratio 12h | GenBank Accession |
|--|--|---------------------------------|----------------------------------|----------------------|
| Other metabolic pathways | | | | |
| <i>Fasn</i> | Fatty acid synthase | -1.46 | NO | BC046513 |
| <i>Alas1</i> | Aminolevulinic acid synthase 1 | -1.02 | NO | NM_020559 |
| <i>Ogt</i> | O-linked N-acetylglucosamine (GlcNAc) transferase (UDP-N-acetylglucosamine:polypeptide-N-acetylglucosaminyl transferase) | -0.65 | -0.57 | BC057319 |

Probability of type I error $\alpha=0.05$. NO – no differential expression was observed.

Table 4

Inflammation markers in water- (Control) or acrolein-treated (5 mg/kg) mice.

| Parameter | Control | ACRO | organ/source |
|-------------------------|------------|---------------|---------------------------|
| CRP ¹ | 448.7±13.3 | 438.0±19.1 | liver |
| SAA ¹ | <1.0 | 353.1±166.8 * | liver |
| Fibrinogen ² | 2,317±39 | 1,310±542 | liver |
| Leptin ³ | 74.9±8.3 | 21.9±8.0 * | adipose |
| ICAM-1 ¹ | 30.7±1.3 | 20.6±2.7 * | vascular |
| VEGF ³ | 2.1±0.2 | 3.4±0.3 * | vascular |
| IL-1β ³ | 19.6±4.4 | 22.9±5.6 | inflammatory cells |
| IL-6 ³ | 5.9±1.3 | 20.6±4.2 * | liver, inflammatory cells |
| IL-10 ³ | 8.7±4.8 | 3.9±0.1 | inflammatory cells |
| TNF-α ³ | 9.8±3.4 | 11.1±1.6 | inflammatory cells |

Values = mean ± S.E.; Units:

¹
[ng/ml];²
[μg/ml];³
[pg/ml]; n=3 mice per group.*
p<0.05 treatment versus control.

Table 5

Effect of simvastatin (SIM; 40 mg/kg) on acrolein (ACRO) toxicity.

| Parameter | Control (4) | SIM (5) | ACRO (4) | SIM+ACRO (5) |
|----------------------------|--------------------|----------------|-----------------|---------------------|
| Cholesterol ¹ | 68.8±13.2 | 82.5±6.9 | 90.7±6.0* | 91.3±1.5* |
| Phospholipids ¹ | 188.6±20.9 | 192.0±11.7 | 241.4±20.8* | 235.3±9.0* |
| Triglycerides ¹ | 37.4±7.9 | 44.6±5.8 | 214.0±44.0* | 125.6±27.0* |
| Albumin ² | 29.0±2.2 | 32.8±1.1 | 20.6±2.0* | 24.6±1.1* |
| Protein ² | 56.0±5.8 | 57.1±2.3 | 38.8±3.0* | 46.6±1.7* |

Adult C57BL/6 mice were gavage fed either water (Control) or acrolein (ACRO; 5 mg/kg) and changes in the indicated plasma constituents were measured 24h after treatment. Values = mean ± S.E.; Units:

¹
[mg/dl],

²
[g/L]; (n), number of mice;

* significant difference between ACRO or SIM+ACRO treatment and Control values.

Table 6

Effect of simvastatin (SIM; 80 mg/kg) on acrolein (ACRO) toxicity.

| Parameter | Control (5) | SIM (6) | ACRO (6) | SIM+ACRO (6) |
|----------------------------|--------------------|----------------|-----------------|---------------------|
| Cholesterol ¹ | 90.9±16.8 | 92.5±2.8 | 116.7±7.5* | 140.9±1.7* |
| Phospholipids ¹ | 160.2±29.5 | 163.8±5.1 | 208.6±13.0* | 238.4±5.4* |
| Triglycerides ¹ | 39.2±8.4 | 38.6±11.8 | 123.5±36.0* | 161.6±20.6* |
| Albumin ² | 27.9±0.5 | 29.6±0.2 | 22.0±0.9* | 19.1±1.2* |
| Protein ² | 39.8±0.3 | 41.6±1.4 | 34.1±1.8* | 31.8±1.7* |

Adult C57BL/6 mice were gavage fed either water (Control) or acrolein (ACRO; 5 mg/kg) and changes in the indicated plasma constituents were measured 24h after treatment. Values = mean ± S.E.; Units:

¹
[mg/dl],

²
[g/L]; (n), number of mice;

* significant difference between ACRO or SIM+ACRO treatment and Control values.